FIELD: chemistry.
SUBSTANCE: invention relates to crystalline form II of 3-ethyl-4-{3-isopropyl-4-(4-(1-methyl-1H-pyrazol-4-yl)-1H-imidazol-1-yl)-1H-pyrazolo[3,4-b]pyridin-1-yl}benzamide, which is stable and has an ability to be absorbed in the oral cavity. Crystalline form II of 3-ethyl-4-{3-isopropyl-4-(4-(1-methyl-1H-pyrazol-4-yl)-1H-imidazol-1-yl)-1H-yrazolo[3,4-b]pyridin-1-yl}benzamide, shows an X-ray powder diffraction spectrum having characteristic diffraction peaks at angles of (2θ ± 0.2°), selected from a group consisting of 7.7°, 8.0°, 11.1°, 12.5°, 12.9°, 15.2°, 15.8°, 17.2°, 19.0°, 22.5°, 26.1° and 27.4°.
EFFECT: invention relates to a method of producing crystalline form II, pharmaceutical compositions thereof, which have HSP90 inhibitory activity and use thereof for treating a tumour.
12 cl, 4 dwg, 3 tbl, 13 ex
| Title | Year | Author | Number |
|---|---|---|---|
| AZABICYCLOCOMPOUND AND ITS SALT | 2010 |
|
RU2565078C2 |
| COMPOUNDS OF 1-CYANO-PYRROLIDINES AS USP30 INHIBITORS | 2016 |
|
RU2717238C2 |
| CANCER CHEMOTHERAPY USING AZABICYCLO COMPOUND | 2018 |
|
RU2821034C2 |
| TYROSINE KINASE INHIBITORS | 2008 |
|
RU2445309C2 |
| PHENOXYMETHYL DERIVATIVES | 2016 |
|
RU2746481C1 |
| mTOR KINASE INHIBITORS FOR ONCOLOGICAL INDICATIONS AND DISEASES METABOLICALLY BOUND TO mTOR/PI3K/AKT | 2009 |
|
RU2546658C2 |
| MTOR KINASE INHIBITORS FOR ONCOLOGIC INDICATIONS AND DISEASES ASSOCIATED WITH MTOR/PI3K/AKT BY METABOLISM | 2009 |
|
RU2692796C2 |
| COMBINATION CANCER THERAPY USING AZABICYCLO COMPOUND | 2014 |
|
RU2657783C2 |
| APOPTOSIS INDUCING AGENTS FOR TREATING CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | 2010 |
|
RU2538965C2 |
| OCTAHYDRO FUSED AZADECALIN GLUCOCORTICOID RECEPTOR MODULATORS | 2014 |
|
RU2674983C1 |
